Tag: GenMab

October 16, 2018

Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2018

Genmab (Nasdaq:GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 498...
June 13, 2018

Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin

Seattle Genetics (Nasdaq:SGEN) announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety...
January 23, 2018

Genmab Announces 2017 Net Sales Figures for DARZALEX®

Genmab (Nasdaq:GEN) announced that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,242 million...
January 22, 2018

U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma

Genmab (CPH:GEN) announced that the U.S. Food and Drug Administration has granted Priority Review to the supplemental Biologics License Application...
September 30, 2016

Genmab’s Financial Calendar for 2017

Genmab, a biotechnology company, today announces its financial calendar for 2017.
May 10, 2016

Genmab Announces Financial Results for the First Quarter of 2016

May 10, 2016; Copenhagen, Denmark; Interim Report for the First Quarter of 2016 Net Sales of DARZALEX® (daratumumab) by Janssen...
April 20, 2016

Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting

Company Announcement Oral plenary session presentation on daratumumab Phase III Castor study data Trial in progress poster presentation from Phase...